Re-treatment From a Phase I Study of MSC-AFP in Patients With Perianal Fistulas

Phase 1CompletedNCT03209700

William A. Faubion, M.D.7 enrolled

Overview

This study is an extension to re-treat partial and non-responders from the previously approved Phase 1 MCS-AFP protocols IRB #12-009716 (Crohn's Disease perianal fistulas) and 15-003200 (cryptoglandular perianal fistulas). This study will enroll patients that have persistent symptomatic perianal disease despite being treated with an MSC coated fistula plug, and also treat patients that have had recurrence of their perianal fistula. As per the previously approval treatment under IND 15356, patients will have a single affected fistula treated, which is the same fistula that was treated in the original protocol. The matrix for delivering the cells is a Gore Bio-A Fistula Plug. Subjects will be screened at outpatient clinic visits and interested qualified subjects will be offered participation in the trial and consented. At the first study visit (Visit 1; Screening visit), the patient will be evaluated and assessment will be made if an EUA is clinically necessary to assess the fistula. As this is a re-treatment trial, patients with incomplete response to initial plug placement typically have close follow up, recent MRI imaging, and may have a seton in place. If an EUA is clinically indicated, this would be by a colorectal surgeon for drainage of sepsis and placement of a seton as part of the standard clinical care for perianal fistula. Patients will return on: Day 1, Week 4, Week 12, and Week 24.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Perianal Fistula Cryptoglandular Perianal Fistula Crohn's Perianal Fistula

Interventions

MSC-AFPDRUG

Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria 1. Males and females 18-65 years of age. 2. Residents of the United States. 3. Single draining perianal fistula for at least three months despite standard therapy 4. Concurrent therapies are permitted (such as antibiotics, corticosteroids, thiopurines). 5. Have no contraindications to MR evaluations: e.g. pacemaker or magnetically active metal fragments, claustrophobia 6. Ability to comply with protocol 7. Competent and able to provide written informed consent 8. Patients that were treated with an MSC-coated fistula plug in the study IRB#12-009716 or IRB#15-003200 Exclusion Criteria 1. Inability to give informed consent. 2. Clinically significant medical conditions within the six months before administration of MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the patient. 3. Specific exclusions: Evidence of hepatitis B, C, or HIV 4. History of cancer including melanoma (with the exception of localized skin cancers) 5. Investigational drug within thirty (30) days of baseline 6. A resident outside the United States 7. Previous allergic reaction to a perianal fistula plug. 8. Allergic to local anesthetics 9. Pregnant patients or trying to become pregnant or breast feeding. 10. Non-enterocutaneous tracts (i.e. recto-vaginal, entero-vesicular)

Locations (1)

Mayo Clinic in Minnesota

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Number of participants with treatment-related adverse events (safety and toxicity).

Participants will have a health assessment and blood work measured at each study visit to monitor for adverse events, such as worsening of the perinal fistulizing disease, abnormal laboratory values, or significant abnormalities in physical examination. The Outcome Measure will be the number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment

Time frame: 6-12 months

Secondary Outcomes

Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.

Participants will have a clinical assessment of fistula drainage. Participants will be assessed during an office examination if their fistula is draining or not. The Outcome Measure will be the presence or absence of fistula drainage.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.